INVENTIVA news, videos and press releases - Page 3
For more news please use our advanced search feature.
INVENTIVA - More news...
INVENTIVA - More news...
- Results of the votes of the Combined Shareholders’ Meeting of April 16, 2021
- Inventiva's Combined Shareholders Meeting of April 16, 2021 - Availability of the preparatory documents and methods for participating and voting
- Inventiva announces filing of its 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
- 2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
- Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen
- Full-Year 2020: Cash position and revenues
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
- Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis
- Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference
- Inventiva receives positive FDA feedback to advance its lead drug candidate lanifibranor into pivotal Phase III in NASH
- Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference
- Inventiva receives FDA Fast Track designation in MPS VI for its clinical-stage asset odiparci
- Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
- H1 2020 financial results and corporate business update
- Inventiva to participate at several investor conferences in September 2020
- Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
- Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market
- Inventiva Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing
- Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2 diabetes patients (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)
- Inventiva files registration statement for proposed initial public offering in the United States
- Inventiva’s lanifibranor meets the primary and key secondary endpoints in the Phase IIb NATIVE clinical trial in non-alcoholic steatohepatitis (NASH
- Inventiva secures a new patent for lanifibranor in China expanding the protection of its lead product candidate
- Inventiva secures €10.0 m non-dilutive loan facility guaranteed by the French State in the context of the COVID-19 pandemic
- Q1 2020 Financial Information
- Shareholders Meeting of May 28, 2020 - Availability of the preparatory documents and methods for participating and voting at the meeting
- Inventiva to provide an update on the NATIVE Phase IIb clinical trial in NASH during a Key Opinion Leader webcast
- Inventiva files a prospectus in the context of the admission to trading of new shares on Euronext Paris
- Inventiva completes a capital increase of €15 m subscribed by existing shareholders
- Inventiva selected to present the positive results from its Phase IIa clinical study with odiparcil in MPS VI at the 16th Annual WORLDSymposiumTM
- Inventiva to present at the Jefferies 2019 London Healthcare Conference
